NCT03075410View on ClinicalTrials.gov

First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 2, 2017

Primary Completion Date

August 4, 2017

Study Completion Date

August 4, 2017

Conditions
Tuberculosis
Interventions
DRUG

GSK3036656

GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.

DRUG

Placebo

Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.

Trial Locations (2)

NW10 7EW

GSK Investigational Site, London

NW10 7

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03075410 - First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects | Biotech Hunter | Biotech Hunter